High-dose flu vaccine better protects HIV-infected adults

High-dose flu vaccine better protects HIV-infected adults
HIV-infected adults achieve higher rates of seroprotection when immunized with a high-dose of the influenza trivalent vaccine compared to the standard dose, according to a study published in the Jan. 1 issue of the Annals of Internal Medicine.

(HealthDay)—HIV-infected adults achieve higher rates of seroprotection when immunized with a high-dose of the influenza trivalent vaccine compared to the standard dose, according to a study published in the Jan. 1 issue of the Annals of Internal Medicine.

Noah McKittrick, M.D., from University of Pennsylvania in Philadelphia, and colleagues randomly assigned 190 HIV-infected persons (older than 18 years) to receive either a standard dose (15 mcg of antigen per strain; 93 participants) or a high dose (60 mcg/strain; 97 participants) of the influenza trivalent vaccine. The rate of seroprotection was assessed, defined as antibody titers of 1:40 or greater on the hemagglutination inhibition assay 21 to 28 days after vaccination. Seroconversion, defined as a greater than four-fold increase in antibody titers, and the geometric mean antibody titer were also assessed.

The researchers found that, in the high-dose group, seroprotection rates were higher for H1N1 (96 versus 87 percent; P = 0.029), H3N2 (96 versus 92 percent; P = 0.32), and (91 versus 80 percent; P = 0.030) strains. Both standard- and high-dose vaccines were well tolerated, with the most frequent being myalgia (19 percent), malaise (14 percent), and local pain (10 percent).

"The implications of this research are important for future vaccination efforts in the HIV-positive population," the authors write. "This study suggests that a substantial number of HIV-infected patients may not be obtaining sufficient protection with the standard ."

More information: Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Third MMR vaccine dose can curtail mumps outbreak

Nov 05, 2012

(HealthDay)—Administering a third dose of the measles-mumps-rubella (MMR) vaccine reduced the village-wide attack rate by about 75 percent in a community experiencing a large mumps outbreak despite a high ...

Young children respond well to recommended swine flu vaccine

May 28, 2010

The first head to head study of the two H1N1 vaccines used in the UK during the recent pandemic finds that the adjuvanted split virus vaccine induced higher immune response rates in young children, but was associated with ...

Dose-escalated cetuximab tolerated in colorectal cancer

Jul 05, 2012

(HealthDay) -- For patients with irinotecan-refractory metastatic colorectal cancer (CRC), dose escalation of cetuximab is well tolerated and may improve response and disease control rates, but patients experience ...

Recommended for you

HIV+ women respond well to HPV vaccine

Apr 16, 2014

HIV-positive women respond well to a vaccine against the human papillomavirus (HPV), even when their immune system is struggling, according to newly published results of an international clinical trial. The study's findings ...

User comments